Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?
10:50am, Tuesday, 28'th Sep 2021
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?
10:44am, Wednesday, 22'nd Sep 2021
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Why Bausch Health Companies Stock Zoomed 8% Higher Today
04:34pm, Tuesday, 21'st Sep 2021
One analyst crunches the numbers to come up with a share price valuation well above current levels.
Is Now the Time to Ditch Pharma Stocks?
06:45am, Tuesday, 21'st Sep 2021
With drug pricing reform on the horizon, investors may want to analyze their allocation.
What Investors Can Learn From Bill Ackman's Turnaround
12:27pm, Wednesday, 15'th Sep 2021
Bill Ackman (Trades, Portfolio) was one of Wall Street's rising stars after the financial crisis. He made a name for himself by making two significant bets the rest of the market seems to have overloo
Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
05:27pm, Monday, 13'th Sep 2021
Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
Bausch Health files confidentially for IPOs of eye care business and medical aesthetics business
08:48am, Monday, 13'th Sep 2021
Bausch Health Cos. Inc. BHC, -0.59% said Monday it has filed confidentially for the initial public offerings of its eye health business Bausch & Lomb, and its medical aesthetics business Global Solta.
Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters
02:44pm, Friday, 10'th Sep 2021
Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA firs
Activist Spotlight: Activists In Bausch Health With Catalysts On Horizon
06:02pm, Tuesday, 31'st Aug 2021
Activists are circling the company and pressuring to unlock shareholder value. Stock still looks attractive from a valuation and near-term catalyst standpoint.
Francis Chou's Chou Associates Fund Semiannual 2021 Letter
05:36pm, Friday, 27'th Aug 2021
August 20, 2021
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
07:39pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch or the "Company") (NYSE: BHC). Such inves
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
12:10pm, Tuesday, 17'th Aug 2021
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
11:33pm, Wednesday, 11'th Aug 2021
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch or the "Company") (NYSE: BHC). Such investors are advi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
08:14pm, Monday, 09'th Aug 2021
New York, New York--(Newsfile Corp. - August 9, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch or the "Company") (NYSE: BHC). Such invest
Why Bausch Health Stock Is On Sale Again
03:55pm, Monday, 09'th Aug 2021
BHC fell after posting quarterly earnings.
